The New York Times
Genentech, the biotechnology company, appears to have resolved a dispute with ophthalmologists that will allow its drug Avastin to continue to be used to treat eye diseases, boths sides announced on Thursday. Genentech had infuriated many eye doctors in October when it announced a change in the distribution of Avastin that would have made it difficult for eye doctors to use the drug.